The latest Investing Matters Podcast episode featuring financial educator and author Jared Dillian has been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksEden Regulatory News (EDEN)

Share Price Information for Eden (EDEN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 4.30
Bid: 0.00
Ask: 0.00
Change: 0.00 (0.00%)
Spread: 0.40 (9.756%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 4.30
EDEN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Grant of Awards under Long-Term Incentive Plan

31 Aug 2023 18:25

RNS Number : 0270L
Eden Research plc
31 August 2023
 

31 August 2023

 

Eden Research plc

 

("Eden" or "the Company")

 

Grant of Awards under Long-Term Incentive Plan

 

Eden Research plc (AIM: EDEN), the AIM-quoted company focused on sustainable biopesticides and plastic-free formulation technology for use in global crop protection, animal health and consumer products industries, confirms the grant of options under the Company's Long Term Incentive Plan ("LTIP") to Sean Smith, Chief Executive Officer, and Alex Abrey, Chief Finance Officer (together the "Executives"), as follows:

 

The Company has made a grant to the Executives, in respect of 2022 in order to ensure continuity of long term incentive, of options over 8,698,909 new Ordinary Shares in Eden ("the Options"), at a strike price of 5.05p each, being the 2022 Volume Weighted Average Price, in the amounts of 4,968,000 awarded to Sean Smith and 3,730,909 awarded to Alex Abrey.

 

The Options expire on 31 August 2027 and vest as follows:

 

1/3 upon grant

1/3 12 months from the date of grant

1/3 24 months from the date of grant

 

The notifications below, made in accordance with the requirements of the EU Market Abuse Regulation, provide further detail.

 

Separately, the Board has agreed that it will extend the exercise date to 31 December 2023 for the 3,500,000 options (2,000,000 awarded to Sean Smith and 1,500,000 awarded to Alex Abrey) with a strike price of 6p which were granted to the Executives in April 2021 under the Company's LTIP and which were due to expire on 30 June 2023.

 

The extension has been agreed to due to the unusually long closed period that the Executives were placed in prior to the options' expiration date.

 

 

For further information contact:

 

Eden Research plc

www.edenresearch.com

Sean SmithAlex Abrey

 

01285 359 555

Cenkos Securities plc (Nominated advisor and broker)

 

Giles Balleny / Max Gould (corporate finance)Michael Johnson (sales)

 

020 7397 8900

Hawthorn Advisors (Financial PR)

 

Simon Woods

Felix Meston

eden@hawthornadvisors.com

 

 

1

 

Details of the person discharging managerial responsibilities / person closely associated

 

a)

 

Name

Sean Smith

2

 

Reason for the notification

 

a)

 

Position/status

 

Chief Executive Officer

b)

 

Initial notification /Amendment

 

Initial Notification

3

 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

 

a)

 

Name

 

Eden Research plc

b)

 

LEI

 

213800ZWTYTVQQSM3J85

4

 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

 

Description of the financial instrument, type of instrument

Identification code

 

Options over ordinary shares of 1 pence each

 

 

GB0001646941

b)

 

Nature of the transaction

 

Grant of options

c)

 

Price(s) and volume(s)

 

Price(s)

 

Volume(s)

5.05p

4,968,000

d)

 

Aggregated information

- Aggregated volume

- Price

 

 

 

N/A

e)

 

Date of the transaction

 

31 August 2023

f)

 

Place of the transaction

 

Outside of trading venue

 

 

 

1

 

Details of the person discharging managerial responsibilities / person closely associated

 

a)

 

Name

Alex Abrey

2

 

Reason for the notification

 

a)

 

Position/status

 

Chief Financial Officer

b)

 

Initial notification /Amendment

 

Initial Notification

3

 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

 

a)

 

Name

 

Eden Research plc

b)

 

LEI

 

213800ZWTYTVQQSM3J85

4

 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

 

Description of the financial instrument, type of instrument

Identification code

 

Options over ordinary shares of 1 pence each

 

 

GB0001646941

b)

 

Nature of the transaction

 

Grant of options

c)

 

Price(s) and volume(s)

 

Price(s)

 

Volume(s)

5.05p

3,730,909

d)

 

Aggregated information

- Aggregated volume

- Price

 

 

 

N/A

e)

 

Date of the transaction

 

31 August 2023

f)

 

Place of the transaction

 

Outside of trading venue

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DSHSDDFWFEDSEEA
Date   Source Headline
29th Jun 202212:18 pmRNSResult of AGM
29th Jun 20227:00 amRNSAGM Statement
8th Jun 20227:12 amRNSNotice of AGM & Publication of Annual Report
7th Jun 20227:00 amRNSInvestor Meet Company: 2021 Results Presentation
31st May 202210:29 amRNSDirector/PDMR Shareholding
31st May 20227:00 amRNSPreliminary results
16th May 20225:05 pmRNSHolding(s) in Company
10th May 20227:00 amRNSRegulatory update
2nd Mar 20227:00 amRNSTrading Update
2nd Dec 20217:00 amRNSNew Major Crop Use for Mevalone in France
20th Oct 20217:00 amRNSAdmission to the US OTC Market
28th Sep 20217:00 amRNSHalf Yearly Report
24th Sep 202112:32 pmRNSNotice of General Meeting
1st Sep 20217:00 amRNSIssuing of Annual Report & Notice of GM
26th Aug 20217:00 amRNSNew label extension for biofungicide in Portugal
28th Jul 20212:53 pmRNSDirector/PDMR Shareholding
27th Jul 20217:00 amRNSAgreement with Sipcam in North Africa
23rd Jul 20217:00 amRNSGrant of Awards under Long-Term Incentive Plan
12th Jul 20214:10 pmRNSHolding(s) in Company
5th Jul 20217:00 amRNSRegulatory approvals
1st Jul 202112:19 pmRNSPublication of Report and Accounts
30th Jun 202112:03 pmRNSResult of AGM
30th Jun 20217:00 amRNSPreliminary Results for Year Ended 31 Dec 2020
29th Jun 202111:27 amRNSVirtual Investor Conference – Link for webinar
7th Jun 20213:28 pmRNSNotice of AGM, investor conference & Accounts
12th May 20217:00 amRNSMilestone Agreement signed with Corteva
10th May 20217:00 amRNSRegulatory approval for Cedroz™ in Italy
1st Apr 20217:00 amRNSGrant of Awards under Long-Term Incentive Plan
31st Mar 20217:00 amRNSNew authorisations for bio-fungicide in Spain
29th Mar 20211:27 pmRNSHolding(s) in Company
19th Feb 20214:41 pmRNSSecond Price Monitoring Extn
19th Feb 20214:35 pmRNSPrice Monitoring Extension
19th Feb 20212:05 pmRNSSecond Price Monitoring Extn
19th Feb 20212:01 pmRNSPrice Monitoring Extension
11th Feb 20219:05 amRNSSecond Price Monitoring Extn
11th Feb 20219:00 amRNSPrice Monitoring Extension
11th Feb 20217:00 amRNSYear end trading update
5th Jan 20217:00 amRNSGreen Economy Mark
2nd Nov 20207:00 amRNSEden partners with M H Poskitt
13th Oct 20207:00 amRNSChange of Registered Office
29th Sep 20207:00 amRNSHalf-year Report
17th Sep 20207:00 amRNSNew authorisations for Cedroz™ and Mevalone®
15th Sep 20207:00 amRNSKey patent granted for Eden’s Sustaine technology
1st Sep 20207:00 amRNSRegulatory approval for Cedroz™ in Spain
25th Aug 20207:00 amRNSNew authorisation for bio-fungicide in Australia
5th Aug 20207:00 amRNSNew authorisation for Cedroz™ in Greece
10th Jul 20207:00 amRNSAppointment of Global Head of Biology and Dev
1st Jul 20207:00 amRNSNew office and laboratory in Oxfordshire
25th Jun 20207:00 amRNSPatents granted in the United States
24th Jun 202012:20 pmRNSResult of AGM

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.